Clinical Trial Update: Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study

View source ↗

Summary

Completed clinical trial evaluating the Venous Excess Ultrasound Score (VExUS) as part of haemodynamic risk assessment in pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Snippet

Sponsor: Istanbul University - Cerrahpasa | Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Status: COMPLETED